BRD9-SMAD2/3 orchestrates stemness and tumorigenesis in pancreatic ductal adenocarcinoma

Journal article

Background and Aims

The dismal prognosis of pancreatic ductal adenocarcinoma (PDAC) is linked to the presence of pancreatic cancer stem-like cells (CSCs) that respond poorly to current chemotherapy regimens. The epigenetic mechanisms regulating CSCs are currently insufficiently understood, which hampers the development of novel strategies for eliminating CSCs.

Methods

By small molecule compound screening targeting 142 epigenetic enzymes, we identified that bromodomain-containing protein BRD9, a component of the BAF histone remodeling complex, is a key chromatin regulator to orchestrate the stemness of pancreatic CSCs via cooperating with the TGFβ/Activin-SMAD2/3 signaling pathway.

Results

Inhibition and genetic ablation of BRD9 block the self-renewal, cell cycle entry into G0 phase and invasiveness of CSCs, and improve the sensitivity of CSCs to gemcitabine treatment. In addition, pharmacological inhibition of BRD9 significantly reduced the tumorigenesis in patient-derived xenografts mouse models and eliminated CSCs in tumors from pancreatic cancer patients. Mechanistically, inhibition of BRD9 disrupts enhancer-promoter looping and transcription of stemness genes in CSCs.

Conclusions

Collectively, the data suggest BRD9 as a novel therapeutic target for PDAC treatment via modulation of CSC stemness.

Authors: Feng, Y; Cai, L; Pook, M; Liu, F; Chang, C-H

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Elsevier
• Journal: Gastroenterology
• Volume: 166
• Issue: 1
• Pages: 139-154
• Place of publication: United States
• Publication date: 2023-09-20
• Acceptance date: 2023-09-11
• DOI: 10.1053/j.gastro.2023.09.021
• EISSN: 1528-0012
• ISSN: 0016-5085
• Pmid: 37739089
• Language: English
• Keywords: pancreatic cancer; cancer stem cells; epigenetics; TGFβ/Activin-SMAD2/3; cancer therapy